



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: samrat@bom4.vsnl.net.in

14 August, 2018

To,
**Department of Corporate Services,
Bombay Stock Exchange Limited**
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Un-Audited Financial Results f.t.q.e. 30/06/2018

We write this to inform you that at a Board Meeting held today i.e. Tuesday, the 14th day of August, 2018, the Board has considered and adopted the attached Un-Audited Financial Results of the company for the quarter ended 30th June, 2018. The Limited Review Report of the Statutory Auditor is also attached.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited


Lalit Mehta
Managing Director





Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat
Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2018

(Rupees in Lakhs)

Particulars	Quarter Ended	
	30-Jun-18 (Unaudited)	30-Jun-17 (Unaudited)
1 (a). Revenue from Operations	2,470.31	2,021.90
(b). Other Income	20.97	1.63
Total Revenue	2,491.28	2,023.53
2. Expenditure		
a) Cost of materials consumed	2,352.24	1,834.80
b) Purchase of Traded Goods	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	(19.89)	(62.15)
d) Employee Costs	27.10	26.92
e) Interest	24.33	19.48
f) Depreciation & Amortisation expense	10.24	10.32
g) Other Expenses	83.29	93.17
Total Expenses	2,477.31	1,922.54
3. Profit before exceptional & extraordinary items & tax	13.97	100.99
4. Exceptional Items	0.00	0.00
5. Profit before extraordinary items & tax	13.97	100.99
6. Extraordinary items	0.00	0.00
7. Profit before tax	13.97	100.99
8. Tax expense		
a) Current Tax	(3.60)	(30.29)
b) Deferred Tax	(6.17)	(11.03)
Total Tax Expense	(9.77)	(41.32)
9. Profit (Loss) for the period after tax	4.20	59.67
10. Other Comprehensive Income (OCI)		
a(i) Items that will not be re-classified to profit and loss	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00
11. Total Comprehensive Income for the period	4.20	59.67
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97
13. Earnings per equity share		
a) Basic	0.14	1.93
b) Diluted	0.14	1.93

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2018
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Tuesday, 14 August 2018 at the Corporate Office of the Company.
4. Figures for the previous period have been regrouped / reclassified, wherever necessary.

Place : Mumbai
Date : 14 August 2018

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director
DIN: 00216731





Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Ashit Shah
Indirect Tax

CA Deepali Mehta
Indirect Tax

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance

LIMITED REVIEW REPORT

**To Board of Directors
Samrat Pharmachem Limited**

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th June, 2018 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financials statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.
3. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For SHAH & SAVLA LLP
Chartered Accountants
Firm Reg: No.:109364W**

**CA. Miral H. Nagda
(Partner)**

Membership No. 108135



Place: Mumbai

Date: **14 AUG 2018**